Evidence map›Paper›PMID 30062629›Full record

ReviewInflammopharmacology2018

Influence of disease-modifying antirheumatic drugs on oxidative and nitrosative stress in patients with rheumatoid arthritis.

Neide Tomimura Costa, Tatiana Mayumi Veiga Iriyoda, Daniela Frizon Alfieri, Andréa Name Colado Simão, Isaias Dichi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Neide Tomimura CostaDepartment of Rheumatology, University of Londrina, Londrina, Paraná, Brazil.ORCID http://orcid.org/0000-0001-6624-2043
Tatiana Mayumi Veiga IriyodaDepartment of Rheumatology, Pontifícia Universidade Católica (PUC), Londrina, Paraná, Brazil.ORCID http://orcid.org/0000-0002-0801-3098
Daniela Frizon AlfieriResearch Laboratory of Applied Immunology, University of Londrina, Londrina, Paraná, Brazil.ORCID http://orcid.org/0000-0002-0217-9329
Andréa Name Colado SimãoResearch Laboratory of Applied Immunology, University of Londrina, Londrina, Paraná, Brazil.ORCID http://orcid.org/0000-0002-2073-6782
Isaias DichiDepartment of Internal Medicine, University of Londrina, Robert Koch Avenue no. 60 Bairro Cervejaria, Londrina, Paraná, CEP: 86038-440, Brazil. dichi@sercomtel.com.br.ORCID http://orcid.org/0000-0002-9127-8264
Universidade Estadual de Londrina · BRPontifícia Universidade Católica do Paraná · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNitro-oxidative stress plays a central role in the pathogenesis of rheumatoid arthritis (RA) and several articles show correlation with disease activity. However, the influence and mechanisms by which disease-modifying antirheumatic drugs (DMARDs) may interfere with nitro-oxidative stress are poorly understood.

objectiveTo show the available data on the effect of the DMARDs on the nitro-oxidative stress in RA patients.

methodsA bibliographic search was carried out in the electronic databases PUBMED, Lilacs, Scientific Electronic Library Online (SCIELO), and Science Direct and the research was limited to human studies, independently of the publication date.

resultsMost studies were performed with infliximab (IFX, 4 articles), tocilizumab (TCZ, 3 articles) and methotrexate (MTX, 2 articles). MTX and leflunomide showed similar results with reduction of nitric oxide. The studies with TCZ verified a marked decrease of reactive oxygen and nitrogen species. Most studies with IFX found a reduction of protein oxidation, evaluated by protein carbonyl measurement. In the present review, the most remarkable results were observed with the increase of the antioxidant defenses through several markers and antioxidant systems. The only study with etanercept showed very similar results to those obtained with MTX, with decreased pentosidine and oxidative DNA damage.

conclusionsThe majority of the studies reported in this work showed an improvement in the redox state, which could be related to success of the therapy. Thus, oxidative and nitrosative stress markers may be useful to early evaluate the response of DMARDs in patients with RA.

Indexed as

Antibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, RheumatoidEtanerceptHumansInfliximabLeflunomideMethotrexateNitrosative StressOxidative StressAntibodies, Monoclonal, HumanizedAntirheumatic AgentsEtanerceptInfliximabLeflunomideMethotrexatetocilizumabDisease-modifying antirheumatic drugsNitrosative stressOxidative stressRheumatoid arthritis

Identifiers

PMID30062629
OpenAlexW2887844894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.